<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863485</url>
  </required_header>
  <id_info>
    <org_study_id>CM082-CA-I-001</org_study_id>
    <secondary_id>2013L00579、2013L00581</secondary_id>
    <nct_id>NCT01863485</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China</brief_title>
  <official_title>Phase 1 Safety, Tolerability, and Pharmacokinetic Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnewPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AnewPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and&#xD;
      Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and&#xD;
      Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors. After the&#xD;
      maximum tolerated dose (MTD) or the optimal biological dose is identified, an expansion&#xD;
      cohort of ~20 advanced renal cell carcinoma patients will be enrolled to further characterize&#xD;
      the safety and tumor response by CT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the Maximum Tolerated Dose in Chinese patients with advanced solid tumors.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Preliminary biological activity</measure>
    <time_frame>24 months</time_frame>
    <description>clinical tumor response by computed tomography (CT) after treatment with CM082 tablets given as a single agent.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under Curve</measure>
    <time_frame>2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half-life time</measure>
    <time_frame>2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cmax</measure>
    <time_frame>2 months</time_frame>
    <description>Peak concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Tmax</measure>
    <time_frame>2 months</time_frame>
    <description>Time to Cmax</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>CM082</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CM082 tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM082 Tablet</intervention_name>
    <description>CM082 tablets taken orally once a day on 28-day cycles</description>
    <arm_group_label>CM082</arm_group_label>
    <other_name>X-82</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy&#xD;
             that is not responsive to standard therapies or for which there is no effective&#xD;
             therapy.&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  No immuno deficiency.&#xD;
&#xD;
          -  Adequate organ system function, defined as follows:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 x 10**9/L&#xD;
&#xD;
               -  Platelets ≥100 x 10**9/L&#xD;
&#xD;
               -  Hemoglobin ≥10 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the&#xD;
                  upper limit of normal (ULN) if no liver involvement or ≤2.5x the upper limit of&#xD;
                  normal with liver involvement.&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN.&#xD;
&#xD;
          -  At least 4 weeks or 5 half-life after receiving cancer therapy (i.e., chemotherapy,&#xD;
             radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or&#xD;
             tumor embolization.&#xD;
&#xD;
          -  Willingness and ability to comply with trial and follow-up procedures.&#xD;
&#xD;
          -  Ability to understand the nature of this trial and give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not recovered from prior anti-cancer therapy or surgery.&#xD;
&#xD;
          -  Have taken strong cytochrome P450 3A4 inhibitors or inducers in the last 2 weeks.&#xD;
&#xD;
          -  Concomitant use of drugs with a risk of causing prolonged corrected QT interval and/or&#xD;
             Torsades de Pointes.&#xD;
&#xD;
          -  Patients with a history of intolerance to, or significant toxicity with, VEGFR&#xD;
             tyrosine kinase inhibitor(s) (TKI).&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Those in reproductive ages who refuse to use contraception.&#xD;
&#xD;
          -  Those with concurrent condition(e.g. psychological, neuronal, cardiovascular,&#xD;
             respiratory conditions or infections) that in the investigator's opinion would&#xD;
             jeopardize compliance with the protocol.&#xD;
&#xD;
          -  Patients with known central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Presence of active gastrointestinal (GI) disease or other condition that will&#xD;
             interfere significantly with the absorption, distribution, metabolism, or excretion of&#xD;
             CM082 (X-82).&#xD;
&#xD;
          -  Patients with known GI disorders such as vomiting, diarrhea.&#xD;
&#xD;
          -  Patients who are hepatitis B virus positive.&#xD;
&#xD;
          -  Drug abuser.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Wan Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorolanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

